Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05542381 · ClinicalTrials.gov registry record · NA
The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
A NA study of Age-related Macular Degeneration, sponsored by Virginia Polytechnic Institute and State University.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT05542381 is a NA study of Age-related Macular Degeneration that has completed, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 64 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05542381, a NA study of Age-related Macular Degeneration, has completed, sponsored by Virginia Polytechnic Institute and State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients are already receiving an intravitreal injection as a standard of care, but they are consenting to receiving a loteprednol drop following the intravitreal injection. This clinical trial is studying the role of loteprednol (corticosteroid) in reducing pain following intravitreal injections for patients with age-related macular degeneration. As of now, there is no definitive pain management technique following intravitreal injections. Loteprednol is a corticosteroid widely used in ophthalmology to treat pain and inflammation, however, it has not been studied as a treatment for pain following intravitreal injections. Our overall goal is to manage pain to improve quality of care after intravitreal injections. Participants will be given either loteprednol, or artificial tears following one visit for an intravitreal injection to test how effective loteprednol is in pain reduction. Pain levels will be assessed by asking participants over the phone about their pain from a scale of 0 to 10 at three different times over a 1-week period. Artificial tear and medication usage will also be tracked over a 1-week period.
Conditions Studied
Interventions
- DRUG Loteprednol Etabonate Ophthalmic Gel [Lotemax]
- OTHER Refresh Lubricant Eye Drops [Artificial Tears]
Study Locations (1)
Virginia
- Vistar Eye Center - Roanoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2025-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05542381
The ClinicalTrials.gov registry entry for NCT05542381 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is Virginia Polytechnic Institute and State University, which has 104 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Loteprednol Etabonate Ophthalmic Gel [Lotemax] is the first listed.
NCT05542381 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05542381 about?
NCT05542381 is a clinical study titled "The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain". Patients are already receiving an intravitreal injection as a standard of care, but they are consenting to receiving a loteprednol drop following the intravitreal injection. This clinical trial is studying the role of loteprednol (corticosteroid) in reducing pain following intravitreal injections fo...
What is the current status of trial NCT05542381?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2022-12-22. Estimated completion is 2025-05-01.
What conditions does trial NCT05542381 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT05542381?
The interventions under investigation include: Loteprednol Etabonate Ophthalmic Gel [Lotemax] (DRUG), Refresh Lubricant Eye Drops [Artificial Tears] (OTHER).
Who is sponsoring clinical trial NCT05542381?
This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05542381 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.